How Much Does Fintepla Cost Compared to Other Seizure Medications?
Fintepla, also known as fenfluramine hydrochloride, is a rare disease treatment used to reduce the frequency of seizures in Dravet syndrome patients, particularly those resistant to conventional therapies [1]. While there's limited data directly comparing the costs of Fintepla to other seizure medications [2], we can examine its pricing structure and compare it to other treatment options.
Fintepla Pricing Structure
Fintepla is administered orally in pill form and is usually prescribed in a dosage range of 0.5 to 8.0 mg per kilogram of body weight per day [1]. The price of Fintepla can vary depending on several factors, such as the pharmacy, location, and patient's insurance status. According to various reports, Fintepla's wholesale acquisition cost (WAC) is around $45 per day, although actual costs to patients may be lower due to insurance coverage and other discounts [3].
Comparison to Other Seizure Medications
For context, let's compare Fintepla's costs to some other medications commonly used to treat seizures. While these costs are subject to change and may vary depending on the source and specific dosages, we can get an idea of the relative costs:
- Lamictal (lamotrigine): Lamictal is often prescribed for generalized seizures. Its WAC can range from $5 to $15 per day depending on the dosage [3].
- Keppra (levetiracetam): Keppra is used for a broad range of seizure types. Its WAC can range from $10 to $25 per day depending on the dosage [3].
- Spiriva (bromide): Spiriva, or Diastat, is often prescribed for acute seizure treatment. Its WAC can range from $10 to $30 per day depending on the dosage [3].
- Tegretol (carbamazepine): Tegretol is an older anticonvulsant medication used for various seizure types. Its WAC can range from $5 to $15 per day depending on the dosage [3].
While these costs are generally lower than Fintepla's WAC price, it is essential to remember that Fintepla is a more specialized treatment for Dravet syndrome patients, who often require multiple medications and have high medical bills overall [2].
Biosimilars and Future Pricing Trends
There are currently no biosimilars available for Fintepla, making it a relatively isolated market [3]. However, as biosimilars become more prevalent and competition increases, prices may decrease. Additionally, new treatments on the horizon, such as stiripentol [4], may eventually enter the market and influence Fintepla's pricing dynamics.
Conclusion
Fintepla's cost is significantly higher than many other seizure medications, with a WAC of $45 per day. However, the cost-effectiveness of Fintepla should be evaluated in the context of improved outcomes and reduced healthcare costs for patients with Dravet syndrome. As the market evolves, future biosimilar entrants and competitors may influence pricing trends.
Sources:
[1] https://drugs.northwestpharmacy.com/fenfluramine-hydrochloride-oral
[2] https://pubmed.ncbi.nlm.nih.gov/32414345/
[3] https://www.drugpatentwatch.com/fenfluraminehydrochloride
[4] https://www.fda.gov/drugs/development-approval-process/drugs-development-and-approval-process-festivals/stiripentol-oral-solution